News & Videos - AIMMUNE THERAPEUTICS INC.

Aimmune Therapeutics UK Ltd., a biopharmaceutical company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases, today announced that PALFORZIA ® [defatted powder of Arachis hypogaea L., semen (peanuts)] has received the Final Appraisal Determination (FAD) as positive draft guidance for use within the National Health Service (NHS) for the treatment of peanut allergy in patients aged 4 to 17. PALFORZIA is indicated in patients...

Aimmune Therapeutics, Inc., une société Nestlé Health Science qui développe et commercialise des traitements pharmaceutiques pour prévenir, gérer et traiter les maladies liées à l’alimentation et au métabolisme, a présenté aujourd’hui les résultats d’analyses longitudinales évaluant les résultats immunologiques de l’immunothérapie orale (Oral Immunotherapy, OIT) quotidienne à long terme avec PALFORZIA ® [Arachide ( Arachis hypogaea ) Allergen Powder-dnfp] chez les...

Aimmune Therapeutics UK Ltd., une société de Nestlé Health Science qui développe et commercialise des thérapies pharmaceutiques pour prévenir, gérer et traiter les maladies liées à l’alimentation et au métabolisme, a annoncé aujourd’hui qu’elle allait présenter de nouvelles données de satisfaction à l’égard du traitement pour son médicament d’immunothérapie orale, PALFORZIA, à l’occasion du Congrès hybride de l’European Academy of Allergy and Clinical Immunology...

Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE 1 , RAMSES, ARTEMIS 2 ) and three open-label extension (ARC004 3 , ARC008, ARC011) trials of PALFORZIA ® [Peanut ( Arachis hypogaea ) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual...

Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA ® [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy. PALFORZIA is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet and may be continued in patients 18 years of age and older. “Today’s approval is a historic moment for the millions of...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT PR Newswire NEW YORK, Sept. 18, 2020 NEW YORK , Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City , is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") ( AIMT ) relating to the sale of the Company to Sociétés des Produits...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of  Aimmune Therapeutics Inc. (NasdaqGS: AIMT) to Sociétés des Produits Nestlé, S.A. Under the terms of the proposed transaction, shareholders of Aimmune will receive only $34.50 in cash for each share of Aimmune that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Aimmune Therapeutics, Inc. PR Newswire NEW YORK, Aug. 31, 2020 NEW YORK , Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aimmune Therapeutics, Inc. ("AIMT" or the "Company") (NASDAQ: AIMT) in connection with the proposed acquisition of the Company by Sociétés des Produits Nestlé S.A. ("Nestlé"). Under the terms of the acquisition agreement,...

Rowley Law PLLC is investigating potential securities law violations by Aimmune Therapeutics, Inc. (NASDAQ: AIMT) and its board of directors concerning the proposed acquisition of the company by Nestlé S.A. Stockholders will receive $34.50 in cash for each share of Aimmune Therapeutics stock that they hold. The transaction is valued at approximately $2.6 billion and is expected to close in the fourth quarter of 2020. If you are a stockholder of Aimmune Therapeutics, Inc. and are interested in...

(AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune Therapeutics; Is $34.50 a Fair Price? PR Newswire SAN DIEGO, Aug. 31, 2020 SAN DIEGO , Aug. 31, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (NASDAQ: AIMT) breached their fiduciary duties in connection with the proposed sale of the Company to Nestlé S.A. On August 31, 2020 , Aimmune...

Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity value of $2.6 billion. Sociétés des Produits Nestlé, S.A. is a part of Nestlé Health Science (NHSc) and a wholly owned subsidiary...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T. A live webcast of the presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com . A...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2020. “We are encouraged that an increasing number of allergy practices around the country have re-opened since June. As a result, we have also seen a corresponding inflection in our leading indicator launch metrics. Given this momentum, we have initiated...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational highlights. To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in a fireside chat at the Goldman Sachs 41 st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 11:20 a.m. E.T. A live webcast of the fireside chat will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com . A...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will participate in a fireside chat at the RBC Capital Markets 2020 Global Healthcare Conference on Tuesday, May 19, 2020 at 4:50 p.m. E.T. A live webcast of the fireside chat will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com ....

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter ended March 31, 2020. “We have remained in close contact with allergists during the shelter-in-place, and their enthusiasm for initiating PALFORZIA therapy, as they begin to reopen their practices, remains as high as when it was approved in January,” said Jayson Dallas, M.D.,...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Monday, May 11, 2020, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2020, and recent operational highlights. To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode 3077398. To...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the 19 th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 2:50 p.m. E.T. A live webcast of the presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com . A replay will be...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the fourth quarter and full year 2019. “The FDA approval of PALFORZIA was a defining moment for the peanut allergy community and Aimmune, and a culmination of years of commitment to bring an approved treatment to people with potentially life-threatening peanut allergy. We are thrilled to have...